XML 43 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Payments - 2017 Share Incentive Plan (Details) - 2017 Share Incentive Plan - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Jul. 26, 2017
Mar. 31, 2018
Options    
Outstanding at beginning of year (in shares)   294,100
Granted (in shares)   1,543,400
Outstanding at end of year (in shares)   1,837,500
Weighted average exercise price in $ per share    
Outstanding balance at beginning of year (in dollars per share)   $ 6.92
Granted (in dollars per share)   6.18
Outstanding balance at end of year (in dollars per share)   $ 6.29
Stock-Based Compensation Expense    
Share-based compensation expense   $ 400
Options    
Share-Based Payments    
Vesting period   10 years
Stock-Based Compensation Expense    
Weighted-average grant date fair value (in dollars per share)   $ 3.60
Fair Value Assumptions    
Expected term of options (in years)   6 years 1 month 6 days
Dividend yield (as a percent)   0.00%
Weighted-average remaining contractual life   9 years 9 months 18 days
Unrecognized compensation expense    
Total unrecognized compensation related to non-vested options (in dollars)   $ 6,300
Period of recognition of total unrecognized compensation related to options   1 year 10 months 24 days
Options | Minimum    
Fair Value Assumptions    
Expected volatility (as a percent)   60.90%
Risk-free interest rate (as a percent)   2.60%
Term of U.S. treasury securities used to estimate risk free interest rate   5 years
Options | Maximum    
Fair Value Assumptions    
Expected volatility (as a percent)   61.00%
Risk-free interest rate (as a percent)   2.70%
Term of U.S. treasury securities used to estimate risk free interest rate   7 years
SARs    
Share-Based Payments    
Vesting period   10 years
Restricted Stock Units    
Share-Based Payments    
Expiration period if drug is not approved   2 years
Restricted Stock Units    
Granted during the period   339,550
Grant date fair value per share   $ 6.47
Restricted Stock Units | Immediate vesting upon regulatory approval    
Restricted Stock Units    
Percentage that vests during the period   50.00%
Restricted Stock Units | Vesting upon the one-year-anniversary of FDA approval    
Share-Based Payments    
Vesting period   1 year
Restricted Stock Units    
Percentage that vests during the period   50.00%
Restricted Stock Units | Chief Executive Officer    
Options    
Granted (in shares)   67,500
Stock-Based Compensation Expense    
Share-based compensation expense   $ 0
Ordinary Shares    
Share-Based Payments    
Number of shares authorized 3,000,000  
Additional shares authorized 3,438,990  
Shares available for grant   4,891,442
Ordinary Shares | Minimum    
Share-Based Payments    
Annual increase, to be added on the first day of each fiscal year (in shares) 2,000,000  
Annual increase, to be added on the first day of each fiscal year (as a percent) 4.00%